^
Association details:
| Biomarker: | CXCL8 elevation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Serum interleukin 8 (IL-8) may serve as a biomarker of response to immuno-oncology (I-O) therapy.
Excerpt:
Association of serum IL-8 with response to NIVO-based therapy suggests that IL-8 may serve as a clinically useful biomarker to select for pts who can benefit from I-O therapy.
Trial ID:
